A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX)

Category Primary study
JournalJournal of Clinical Oncology
Year 2018
This article has no abstract
Epistemonikos ID: e6549cd491b56797863c385a26f73496f97ffe21
First added on: Feb 10, 2025